A5043944883- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Biosimilars and Bioanalytical Methods
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Vascular Tumors and Angiosarcomas
- Biomedical Text Mining and Ontologies
- Cancer Immunotherapy and Biomarkers
- Childhood Cancer Survivors' Quality of Life
- Palliative Care and End-of-Life Issues
- Histone Deacetylase Inhibitors Research
- Medical Imaging Techniques and Applications
- Bone health and treatments
- Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Acute Lymphoblastic Leukemia research
- Global Cancer Incidence and Screening
University of Michigan
2021-2025
Arbor Research Collaborative for Health
2025
HR Wallingford
2025
Barton Community Health & Care Centre
2025
Michigan Center for Translational Pathology
2022-2024
Michigan United
2024
Michigan Medicine
2022-2024
Jacobi Medical Center
2023
Stanford Medicine
2019-2021
Mayo Clinic in Arizona
2021
Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in management mantle cell lymphoma (MCL), both frontline setting. Anti-CD19 CAR T-cell are now effective approved options for follicular (FL), diffuse large (DLBCL), MCL. Bispecific engagers represent a novel immunotherapeutic approach relapsed FL...
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) 10-13 months. disease fare worse, CR rate 7% for subsequent therapies OS 6 Epcoritamab, CD3xCD20 bispecific antibody approved the treatment R/R DLBCL after ≥2 therapy lines, has shown promising safety efficacy in various...
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)-a rare category defined by morphologic features lack MYC rearrangements BCL2 and/or BCL6 ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% had a germinal center immunophenotype, 37% dual-expressor immunophenotype (MYC expression), 28% rearrangement, 13% 11% rearrangement. Most presented...
Most studies to date exploring facilitators and barriers adolescent young adults' (AYAs') participation in clinical trials have been focused on external factors AYAs' or recruitment strategies. The purpose of this mixed-methods study was determine AYA cancer survivors' preferences for oncology symptom management trial participation. Semistructured interviews conjoint analysis were conducted clarify potential attributes (eg, characteristics) levels value the characteristic) that may be...
Large-scale analysis of real-world evidence is often limited to structured data fields that do not contain reliable information on recurrence status and disease sites. In this report, we describe a natural language processing (NLP) framework uses from free-text, unstructured reports classify sites for patients with breast hepatocellular carcinomas (HCC).Using two cohorts cancer HCC cases, validated the ability previously developed NLP model distinguish between no recurrence, local distant...
7523 Background: Outcomes of pts with newly diagnosed DLBCL high/poor risk according to the revised International Prognostic Index (IPI) treated immunochemotherapy (IC) remain suboptimal, a 4-year survival rate 55% (Sehn et al, Blood 2007). SC epco is well-tolerated bispecific antibody single-agent activity in relapsed/refractory (R/R) aggressive B-cell NHL setting. The mechanism action and safety profile are distinct from IC, well suited for use combinations earlier lines therapy. Addition...
7525 Background: Outcomes are poor for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Effective treatments (tx) that drive deep, durable responses and long-term benefit needed. In the pivotal EPCORE NHL-1 trial (NCT03625037), single-agent epcoritamab (epcor) showed high complete response (CR) MRD-negativity rates, a median duration of (mDoR) not reached (NR) in pts who achieved CR, manageable safety profile as an off-the-shelf, subcutaneous (SC), CD3xCD20...
Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who untreated. Over the last several years, targeted or small-molecule therapies have shown efficacy relapsed/refractory setting since been explored frontline setting. Lenalidomide plus rituximab was phase 2 study 38 MCL were untreated ineligible to receive transplantation, which combination...
Few studies have specifically targeted symptom management interventions for adolescent and young adult (AYA) cancer survivors. A greater understanding of AYA survivors' experiences with treatment-related symptoms would help develop age-appropriate oncology interventions. The purpose this qualitative analysis was to explore experience symptoms.
7032 Background: While high-dose therapy (HDT)–autologous stem cell transplant (ASCT) is potentially curative for pts with R/R DLBCL, many do not receive this treatment (tx) due to insufficient response salvage chemoimmunotherapy; better options are needed. Epcoritamab a CD3xCD20 bispecific antibody efficacy and safety in DLBCL as single agent combination. We report updated data from epcoritamab combination rituximab, dexamethasone, cytarabine, oxaliplatin or carboplatin (R-DHAX/C) eligible...
7039 Background: Epcoritamab induces high complete response (CR) and MRD-negativity rates with manageable safety in patients (pts) challenging-to-treat R/R LBCL as shown the pivotal phase 2 study (NCT03625037). Here we present long-term data, an additional efficacy analysis from expansion cohort, data cycle 1 optimization (C1 OPT) part. Methods: Adults CD20 + ≥2 prior systemic therapies received subcutaneous epcoritamab (2 step-up doses, then 48-mg full doses per label) 28-d Cs. The primary...
7037 Background: Gemcitabine + oxaliplatin (GemOx) is commonly used with rituximab to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, outcomes are suboptimal: 33% complete response (CR) rate; 5 mo median progression-free survival (PFS); 10 overall (OS; Cazelles et al, Leuk Lymphoma 2021). We report additional efficacy and safety results of epcoritamab GemOx in difficult-to-treat R/R DLBCL (EPCORE™ NHL-2 phase 1/2 trial, NCT04663347). Methods: Adults CD20...
7505 Background: MCL is a rare lymphoma without standard of care but several regimens have demonstrated clinical activity, the majority based on traditional chemotherapy. We hypothesized that adding venetoclax (V) to R2 would be safe and effective in pts irrespective age, morphology or stage. Here we present safety efficacy data from on-going phase 1b study + V with newly diagnosed MCL. Methods: This multi-center 1 (NCT03523975) enrolled aged ≥18 yrs untreated The primary objective was...
Introduction: Outcomes are poor for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Effective treatments that drive deep, durable responses and long-term benefit needed. In the pivotal EPCORE™ NHL-1 trial (NCT03625037), single-agent epcoritamab showed high complete response (CR) MRD-negativity rates a manageable safety profile as an off-the-shelf, subcutaneous, CD3xCD20 T-cell–engaging bispecific antibody (Thieblemont et al. J Clin Oncol, 2022). We present updated...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Outcomes are poor for patients with relapsed/refractory (R/R) large B-cell (LBCL). Effective treatments that drive deep, durable responses and long-term benefit needed. In the pivotal EPCORE™ NHL-1 trial (NCT03625037), single-agent epcoritamab showed high complete response (CR) MRD-negativity rates a manageable safety profile as an off-the-shelf, subcutaneous, CD3xCD20 T-cell–engaging bispecific antibody (Thieblemont et al,...